JPMorgan Chase & Co. Reiterates "Neutral" Rating for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Amphastar Pharmaceuticals (NASDAQ:AMPH - Get Free Report)'s stock had its "neutral" rating reiterated by equities researchers at JPMorgan Chase & Co. in a research note issued to investors on Monday,Benzinga reports. They presently have a $30.00 price objective on the stock, down from their prior price objective of $45.00. JPMorgan Chase & Co.'s price target indicates a potential upside of 24.43% from the stock's previous close.

Other research analysts have also recently issued reports about the company. Piper Sandler lowered their price objective on Amphastar Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating on the stock in a research report on Friday, March 21st. Wells Fargo & Company decreased their target price on Amphastar Pharmaceuticals from $40.00 to $35.00 and set an "overweight" rating on the stock in a research note on Thursday. Finally, Needham & Company LLC reissued a "hold" rating on shares of Amphastar Pharmaceuticals in a research note on Thursday, April 10th. Four research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $32.33.

Amphastar Pharmaceuticals Trading Down 2.2%

Shares of NASDAQ:AMPH opened at $24.11 on Monday. The stock has a market capitalization of $1.15 billion, a price-to-earnings ratio of 8.04, a PEG ratio of 2.19 and a beta of 0.78. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.61 and a current ratio of 3.43. The stock's 50-day simple moving average is $25.83 and its two-hundred day simple moving average is $34.66. Amphastar Pharmaceuticals has a 52-week low of $22.64 and a 52-week high of $53.96.

Insider Buying and Selling at Amphastar Pharmaceuticals

In other Amphastar Pharmaceuticals news, CFO William J. Peters sold 4,231 shares of the company's stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $27.54, for a total value of $116,521.74. Following the transaction, the chief financial officer now owns 97,363 shares of the company's stock, valued at $2,681,377.02. This represents a 4.16% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders have sold 5,231 shares of company stock valued at $142,752 in the last quarter. 27.50% of the stock is owned by insiders.

Institutional Investors Weigh In On Amphastar Pharmaceuticals

Hedge funds have recently made changes to their positions in the company. Smartleaf Asset Management LLC lifted its holdings in shares of Amphastar Pharmaceuticals by 222.1% in the 4th quarter. Smartleaf Asset Management LLC now owns 715 shares of the company's stock worth $26,000 after buying an additional 493 shares during the period. Signaturefd LLC lifted its holdings in shares of Amphastar Pharmaceuticals by 147.7% in the 1st quarter. Signaturefd LLC now owns 872 shares of the company's stock worth $25,000 after buying an additional 520 shares during the period. Parkside Financial Bank & Trust lifted its holdings in shares of Amphastar Pharmaceuticals by 806.5% in the 4th quarter. Parkside Financial Bank & Trust now owns 979 shares of the company's stock worth $36,000 after buying an additional 871 shares during the period. GF Fund Management CO. LTD. purchased a new stake in shares of Amphastar Pharmaceuticals during the 4th quarter worth $38,000. Finally, Tower Research Capital LLC TRC lifted its stake in shares of Amphastar Pharmaceuticals by 43.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,145 shares of the company's stock worth $43,000 after purchasing an additional 348 shares during the last quarter. 65.09% of the stock is currently owned by hedge funds and other institutional investors.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.